← Leaderboards
Nai-Kong V Cheung
Sloan-Kettering Institute For Cancer Res
$9,578,208
Attributed
$13,656,876
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$13,656,876 · 9
By mechanism
U01$4,282,428 · 1
R01$4,194,097 · 2
R21$2,587,457 · 4
P01$1,334,484 · 1
P50$1,258,410 · 1
Top collaborators
- Lawrence G Lum6 shared
- Sophie Paczesny3 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Kim Kramer$2,359,989
- George Sgouros$17,275,548
- Barrie R Cassileth$4,322,812
- Irene Y Cheung$317,000
- Philip O. Livingston$8,464,484
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTumorNeuroblastomaAntibodiesCytotoxicityCellsImmuneIn VitroT-LymphocyteMediatingImmunotherapyOsteosarcomaXenograft ProcedureClinical TrialsMonoclonal Antibody 3f8Clinical ResearchIn VivoChemotherapyMouse ModelChildBone MarrowMonoclonal AntibodiesResponseAntigens
Grant awards (28)
Dual targeting of tumoral microenvironment and tumoral cells by blocking the IL-33/ST2 pathway$153,053
U01 · FY2020 · CA
Targeting Neuroblastoma with armed T cells$730,382
R01 · FY2019 · CA
Dual targeting of tumoral microenvironment and tumoral cells by blocking the IL-33/ST2 pathway$2,940,474
U01 · FY2018 · CA
Dual targeting of tumoral microenvironment and tumoral cells by blocking the IL-33/ST2 pathway$1,188,901
U01 · FY2018 · CA
Targeting Neuroblastoma with armed T cells$1
R01 · FY2018 · CA
Targeting Neuroblastoma with armed T cells$765,563
R01 · FY2017 · CA
Targeting Neuroblastoma with armed T cells$822,924
R01 · FY2016 · CA
Targeting Neuroblastoma with armed T cells$753,575
R01 · FY2015 · CA
Targeting Neuroblastoma with armed T cells$802,464
R01 · FY2014 · CA
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-$379,518
R21 · FY2012 · CA · contact PI
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-$372,861
R21 · FY2011 · CA · contact PI
Project 4$314,585
P01 · FY2009 · CA · contact PI
Modulation by Botanicals of Antibody Based Cancer Immunotherapy$269,759
P50 · FY2009 · AT · contact PI
Project 4$307,528
P01 · FY2008 · CA · contact PI
Modulation by Botanicals of Antibody Based Cancer Immunotherapy$145,273
P50 · FY2008 · AT · contact PI
Project 4$332,324
P01 · FY2007 · CA · contact PI
Modulation by Botanicals of Antibody Based Cancer Immunotherapy$283,563
P50 · FY2007 · AT · contact PI
A novel set of molecular markers to measure metastatic neuroblastoma$132,978
R21 · FY2007 · CA · contact PI
Modulation by Botanicals of Antibody Based Cancer Immuno$279,042
P50 · FY2006 · AT · contact PI
Project 4$192,310
P01 · FY2006 · CA · contact PI
A novel set of molecular markers to measure metastatic neuroblastoma$137,850
R21 · FY2006 · CA · contact PI
Modulation by Botanicals of Antibody Based Cancer Immuno$280,773
P50 · FY2005 · AT
Project 4$187,737
P01 · FY2005 · CA
Beta glucan enhances antibody therapy for neuroblastoma$407,500
R21 · FY2003 · CA
Beta glucan enhances antibody therapy for neuroblastoma$407,500
R21 · FY2002 · CA
NOVEL TUMOR ANTIGEN FOR ANTIBODY TARGETING$374,625
R21 · FY2001 · CA
NOVEL TUMOR ANTIGEN FOR ANTIBODY TARGETING$374,625
R21 · FY2000 · CA
NOVEL COMBINATION THERAPY OF NEUROBLASTOMA$319,188
R01 · FY2000 · CA